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ABSTRACT
Genetic variation in CYP3A activity may influence the rate of the
metabolism and elimination of CYP3A substrates in humans.
We previously reported four new CYP3A4 coding variants in
three different racial groups. In the present study, we examined
metabolism of nifedipine by the recombinant forms of these
allelic variants. Metabolism of nifedipine by the L293P
(CYP3A4*18), M445T (CYP3A4*3), and P467S (CYP3A4*19) al-
lelic variants was not significantly different from wild-type
CYP3A4*1. However, F189S (CYP3A4*17) exhibited a 99%
decrease in both Vmax and CLmax of nifedipine compared with
CYP3A4*1. Of 72 racially diverse individuals, CYP3A4*17 was
identified in 1 of 24 Caucasian samples [1:5 Eastern European
(Adygei ethnic group)]. Genotyping of an extended set of 276
genomic DNAs of Caucasians (100 from the Coriell Repository
and an additional 176 from the United States) for CYP3A4*17
detected no additional individuals containing the CYP3A4*17
allele. However, additional genotyping of four more Adygei
samples available from Coriell detected an additional individual
carrying the CYP3A4*17 allele. New specific polymerase chain
reaction-restriction fragment length polymorphism genotyping
procedures were developed for the major splice variant of
CYP3A5 (CYP3A5*3) and CYP3A4*17. Genotyping revealed
that the two individuals carrying CYP3A4*17 were either ho-
mozygous or heterozygous for the more frequent CYP3A5*3
allele, suggesting that the two alleles may exist on the same
chromosome as a new putative CYP3A poor metabolizer hap-
lotype. We predict that individuals who are homozygous for
defective alleles of both of these genes would metabolize
CYP3A substrates poorly. The new genetic tests will be useful
in future clinical studies to investigate genotype/phenotype
associations.
The CYP3A subfamily of cytochrome P450 enzymes com-
prises approximately 30–60% of total cytochrome P450 in
human liver (Shimada et al., 1994). The CYP3A enzymes are
responsible for the metabolism of approximately half of all
clinical drugs, steroids, and environmental chemicals (Li et
al., 1995; Evans and Relling, 1999). Among the four human
CYP3A genes, CYP3A4 is generally believed to be the most
abundant in liver (Wrighton et al., 1990; Shimada et al.,
1994; Hustert et al., 2001; Koch et al., 2002) and to metabo-
lize the majority of clinically used drugs. CYP3A4 catalytic
activity can be modulated by transcriptional induction by
rifampin, phenobarbital, and the herbal antidepressant St.
John’s Wort (Lucey et al., 1990; Gibson et al., 2002) resulting
in decreased drug concentrations in plasma. CYP3A4 activity
can also be inhibited by ketoconazole, erythromycin, a com-
ponent in grapefruit juice, and other compounds (Fukuda et
al., 1997; Thummel and Wilkinson, 1998). A third possible
source of variability is from genetic variations in CYP3A4
and CYP3A5. Current literature indicates that the major
cause of variation in CYP3A5 activity is due to the frequency
of the CYP3A5*3 splice variant (Kuehl et al., 2001) which
affects protein expression in liver and other tissues. How-
ever, CYP3A4 and CYP3A5 have overlapping substrate spec-
ificity (Shimada et al., 1994; Wacher et al., 1995; Thummel
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and Wilkinson, 1998; Kuehl et al., 2001; Williams et al.,
2002). Thus, active CYP3A4 largely compensates for defec-
tive CYP3A5 metabolism and vice versa. Therefore, the con-
comitant presence of defective alleles of both CYP3A4 and
CYP3A5 would be much more likely to affect metabolism of
CYP3A substrates in vivo than mutations in a single CYP3A
gene.
Recently, we reported new coding alleles, CYP3A4*3
(M445T), CYP3A4*15 (R162Q), CYP3A4*17 (F189S),
CYP3A4*18 (L293P), and CYP3A4*19 (P467S), after rese-
quencing CYP3A4 in 72 racially diverse individuals (Dai et
al., 2001). CYP3A5 was later resequenced in the same indi-
viduals (Lee et al., 2003). We originally expressed the coding
variants of CYP3A4 in Escherichia coli, and preliminary
studies compared the ability of these allelic variants to me-
tabolize the hormone testosterone and the insecticide chlor-
pyrifos at only one substrate concentration due to its low
activity in recombinant systems in vitro (Dai et al., 2001).
CYP3A4*17 exhibited lower catalytic activity compared with
wild type for both testosterone and chlorpyrifos (an organo-
phosphate insecticide) metabolism, whereas CYP3A4*18 ex-
hibited higher activity compared with wild type (Dai et al.,
2001). CYP3A4 has multiple substrate binding sites, there-
fore, substrates may be metabolized differently (Gillam et al.,
1995; Domanski et al., 1998; Wang et al., 1998; Williams et
al., 2002). In the present studies, we examine the effect of the
coding alleles of CYP3A4 on the metabolism and kinetics of
the antihypertension drug nifedipine and provide strong ev-
idence that CYP3A4*17 is a putative defective allele, with a
99% decrease in catalytic activity. Sequence analysis of
CYP3A4 and CYP3A5, performed on the same 72 individuals
from our two previous studies (Dai et al., 2001; Lee et al.,
2003), showed that the CYP3A4*17 allele was present in a
single Eastern European (Adygei, one of five individuals)
who was homozygous for the CYP3A5*3 allele, suggesting
these alleles may occur together on one haplotype. In this
study, we have developed a genetic test for the CYP3A4*17
allele which may be useful in future clinical studies. More-
over, a previously published PCR-RFLP test for CYP3A5*3
was found to be unreliable in our hands because of a simi-
larity in the primer sequences with multiple CYP3A genes
(Fukuen et al., 2002; Balram et al., 2003). Therefore, we
developed a new, more specific genotyping method for
CYP3A5*3. In an attempt to verify whether CYP3A4*17 and
CYP3A5*3 occur on a single haplotype in some Caucasians,
DNA from two additional groups of Caucasians totaling 276
individuals was analyzed for the two alleles. In addition,
DNA from nine Adygei, a Caucasian ethnic minority from
Eastern Europe, was also analyzed. The CYP3A4*17 and
CYP3A5*3 alleles were found together in two of nine Adygei,
suggesting that these two alleles occur together as part of a
defective CYP3A haplotype in certain Caucasian ethnic
groups. Individuals homozygous (or heterozygous) for the
defective CYP3A4*17/CYP3A5*3 haplotype would be pre-
dicted to metabolize CYP3A substrates more poorly than
individuals carrying only a defective allele in one CYP3A
gene.
Materials and Methods
Nifedipine, NADPH, -aminolevulinic acid, ampicillin, sodium
cholate, L--dilauroyl-sn-glycero-3-phosphocholine and L--dioleoyl-
sn-glycero-3-phosphocholine, bovine brain phosphatidylserine, phe-
nylmethylsulfonyl fluoride, leupeptin, aprotinin, and lysozyme were
purchased from Sigma-Aldrich (St. Louis, MO). E. coli DH5 com-
petent cells, agarose-1000, and isopropyl -D-thiogalactopyranoside
were purchased from Invitrogen (Carlsbad, CA). Restriction enzymes
and T4 DNA ligase were obtained from New England Biolabs (Bev-
erly, MA). Oligonucleotide primers were obtained from Sigma-Geno-
sys (The Woodlands, TX). Quick-change mutagenesis kit and proof-
reading Pfu DNA polymerase were from Stratagene (La Jolla, CA).
Ni-NTA affinity column was from QIAGEN (Valencia, CA). Imida-
zole was purchased from Calbiochem (San Diego, CA). Human
NADPH-cytochrome P450 oxidoreductase (P450 reductase) and cy-
tochrome b5 were purchased from Oxford Biomedical Research (Ox-
ford, MI). All other chemicals and organic solvents for high-perfor-
mance liquid chromatography were of the highest grade from
commercial sources.
DNA Samples. Genomic DNAs from 72 racially diverse individ-
uals for our earlier resequencing studies of CYP3A4 and CYP3A5
were obtained from lymphoblastoid cell lines selected from the Hu-
man Genetic Cell Repository sponsored by the National Institutes of
Health housed at the Coriell Institute, Camden, NJ (Dai et al., 2001;
Lee et al., 2003). From the present study, a second Human Variation
Panel containing 100 Caucasian genomic DNAs and a third Human
Variation Panel representing nine European Caucasians belonging
to the Adygei ethnic minority were purchased from Coriell Institute,
Camden, NJ. An additional set of 176 genomic DNAs were obtained
from a community-based population of healthy, unrelated Caucasian
volunteers from Durham and Chapel Hill, North Carolina. This
study was approved by the National Institute of Environmental
Health Sciences Institutional Review Board.
Construction of CYP3A4 Single Nucleotide Polymorphism
cDNAs. CYP3A4 variant alleles constructed in pCW (Dai et al.,
2001) were used for PCR templates to incorporate additional modi-
fications. The N-terminal of CYP3A4*1 cDNA had been previously
modified to MALLLAVF as described for bovine 17-hydroxylase
(Barnes et al., 1991). In the present study, an additional PCR was
performed to add a 5 His tag to the C-terminal region of CYP3A4*1
to simplify purification. PCR primers included a forward primer,
5-GGTGGTCATATGGCTCTGTTATTAGCAGTTTTTCTGGTGCTCC-
TCTATC-3 and a reverse primer, 5-GTGGCCTCTAGATCAGTGA TG-
GTGATGGTGGGCTCCACTTACGGTGCC-3. The modified CYP3A4
cDNAs were recloned into the NdeI and XbaI sites of pCW. After
construction of mutants, the entire single nucleotide polymorphism
constructs were analyzed by sequencing in both directions before
expression.
Expression and Purification of CYP3A4s. CYP3A4 wild-type
and variant proteins were expressed in E. coli DH5 cells. Expres-
sion and purification of P450 proteins were performed as previously
described (Lee et al., 2003). Optimal expression conditions for
CYP3A4*1 were determined to be 0.5 mM isopropyl -D-thiogalacto-
pyranoside and 0.5 mM -aminolevulinic acid in Terrific broth for
72 h at 23°C with gentle shaking at 150 rpm. Cytochrome P450
expression was monitored by CO difference spectra measured using
a DW-2000/OLIS spectrophotometer (Omura and Sato, 1964). Max-
imal expression varied from 200 nmol/l for wild type to 80 to 100
nmol/0.5 liter of culture for most mutant alleles. CYP3A4*17 exhib-
ited low expression of 40 nmol. To minimize interexperimental
variations in expression and purification, all five CYP3A4 cDNA
constructs were simultaneously expressed, harvested, and purified
under the same conditions. After solubilization of the membrane
fraction, P450 was purified by a Ni-NTA affinity column utilizing the
histidine tag. The eluted P450 was quantitated and diluted to 1 nmol
of P450 per milliliter to avoid aggregation and precipitation during
dialysis. It was then dialyzed twice for 48 h in two changes of dialysis
buffer (100 mM potassium phosphate, pH 7.4, and 20% glycerol). A
second set of all five purified proteins was generated for the purpose
of comparison. Purification of P450s by Ni-NTA affinity column
chromatography resulted in approximately 40% recovery.
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Reconstitution and Nifedipine Oxidation. CYP3A4 (10 pmol),
human reductase (40 pmol), cytochrome b5 (20 pmol), 0.05 mol of
sodium cholate, and 2 g of lipid mix (L--dilauroyl-sn-glycero-3-
phosphocholines and brain phosphatidyl serine) were preincubated
at room temperature for 10 min and then 50 mM potassium buffer,
pH 7.7 added to a final volume of 0.1 ml (Lee et al., 2003). The
reaction was initiated with 1 mM NADPH and incubated at 37°C for
10 min. Nifedipine was protected from light during the experiment.
Nifedipine concentrations for the kinetic analysis were 6.25, 12.5, 25,
50, 100, 200, and 400 M. There was no catalytic activity in the
absence of NADPH. The oxidized metabolite was analyzed by high-
performance liquid chromatography with a Phenomenex Luna C18
column (5 m, 250  4.6 mm; ANSYS Technologies, Inc., Lake
Forest, CA) as described earlier (Lee et al., 2003).
Development of Genotyping Methods. Genomic DNA se-
quences for CYP3A4, CYP3A5, CYP3A7, and CYP3A43 were ob-
tained from GenBank (accession number NG_000004.1). Before se-
quence alignment, all DNA sequences of CYP3A43 were changed to
reverse complementary sequences using Vector NTI 8.0 due to its
reverse direction of transcription. Sequence alignment was per-
formed using BOXSHADE software version 3.21 in BCM Search
Launcher (http://searchlauncher.bcm.tmc.edu/multi-align/multi-
align.html) and analyzed to design a specific primer. Specific geno-
typing primers for the detection of CYP3A4*17 and CYP3A5*3 are
described in Table 1. Detection of defective alleles was performed by
PCR and restriction enzyme analysis. Genomic DNA (40 ng) was
amplified by PCR containing 0.4 M primers, 0.4 mM of each dNTP,
and 2.5 units of AmpliTaq Gold (PerkinElmer Life and Analytical
Sciences, Boston, MA) in 25-l reactions. Amplification was per-
formed for 38 cycles consisting of denaturation at 94°C for 30 s,
annealing at 56°C for 20 s, and extension at 72°C for 30 s
(CYP3A4*17) or 20 s (CYP3A5*3). An initial denaturation step at
95°C for 10 min and a final extension step at 72°C for 5 min were
performed. Both PCR products were purified by QIAquick PCR Pu-
rification Kit (QIAGEN) and directly sequenced to check the specific
amplification of the target DNA. Five-microliter aliquots of PCR
product for CYP3A4*17 and CYP3A5*3 were directly digested with
BpmI and BseMII (Fermentas Inc., Hanover, MD), respectively.
Since we did not have DNA from an individual homozygous for
CYP3A4*17, the efficiency of BpmI digestion in PCR buffer with
additional 1 restriction enzyme buffer was examined using a
PCR2.1 TOPO plasmid construct containing a PCR-amplified
CYP3A4*17 fragment (using genotyping primers) as a positive con-
trol. Digested PCR products were analyzed on 3% agarose gels.
Analysis of Enzyme Kinetics. Nifedipine oxidation was ana-
lyzed by nonlinear regression using SigmaPlot 2001 (SPSS Inc.,
Chicago, IL) as described earlier (He et al., 2003; Lee et al., 2003).
The goodness of fit was determined by the distribution of residual
patterns, the residual sums of squares, and the standard error of the
parameter estimates. Kinetics for nifedipine metabolism exhibited
the best fit with the Hill equation as reported previously (Williams et
al., 2002). The Hill eq. 1 was used to determine Vmax, S50, and the
Hill coefficient (nH). CLmax, the maximum clearance resulting from
positive cooperativity, was determined using eq. 2 (He et al., 2003;
Lee et al., 2003).
v  VmaxS]nH/SnH50  SnH (1)
v/S  Vmax/S50  n  1/nn  11/nH (2)
Statistical Analysis. Two independently purified P450s for each
allele were assayed in triplicate. The means of the triplicate assays
were compared with the mean of the triplicate wild-type purified
P450 using Dunnett’s test. The assay was repeated on two separate
days. A P value of 	0.05 was considered statistically significant.
Results
The CYP3A4*17 Allele Is Defective in the Metabolism
of Nifedipine. Purified CYP3A4*17 contained some dena-
tured cytochrome P420 (Fig. 1), but none of the other vari-
ants contained P420 after purification. However, metabolic
assays were normalized to P450 content and results should
not be affected by the small amount of denatured P420. Since
kinetic analysis requires large amounts of enzyme, we first
compared the statistical differences in turnover numbers of
CYP3A4 variants by assaying equivalent picomoles of each
allelic variant in triplicate at two different concentrations of
substrate: 30 M which approximates the S50 value of wild-
type CYP3A4 as determined in our laboratory and a high
concentration of 200 M which approaches the Vmax of the
enzyme. Figure 2 shows the representative results of one of
two independent sets of assays. CYP3A4*17 significantly
decreased catalytic activity for nifedipine oxidation by 98 to
99% (P 	 0.05) at the high concentration of nifedipine in both
experiments. At the low substrate concentration, nifedipine
oxidation by CYP3A4*17 was below detection levels. There
was no statistically significant difference in nifedipine oxida-
tion by the other recombinant allelic variants. Figure 3 and
Table 2 compare kinetic parameters for nifedipine oxidation
by the CYP3A4 recombinant mutant allelic proteins with
that of wild type. Kinetic parameters for nifedipine metabo-
lism by CYP3A4*1, CYP3A4*18, CYP3A4*3, and CYP3A4*19
allelic proteins were similar; however, CYP3A4*17 protein ex-
hibited a 99.2 and 99.6% decrease in the Vmax and maximal
clearance, respectively, for nifedipine compared with wild type.
New Genetic Test for CYP3A4*17. A PCR-RFLP geno-
typing test was developed to detect CYP3A4*17. Since there
are four structurally similar CYP3A genes arranged in tan-
dem comprising 230 kb on chromosome seven, PCR primers
were designed to specifically amplify a 290-bp DNA fragment
containing only CYP3A4 (Fig. 4C, lane 5). The TC mutation
present in CYP3A4*17 introduced a BpmI site (Fig. 4A)
which was not present in wild-type CYP3A4. Sequencing of
the amplified PCR product verified the specific amplification
of CYP3A4. The DNA sample heterozygous for CYP3A4*17
produced bands at 290, 153, and 137 bp when digested with
BpmI in PCR buffer (Fig. 4C, lane 3). Complete cutting of the
BpmI site was observed in the presence of PCR buffer with
additional 1 restriction enzyme buffer in the positive con-
TABLE 1
Primers used for genotyping of CYP3A4*17 and CYP3A5*3a
Variant Name Variant Location Primer Name Sequences (533)
CYP3A5*3 Intron 3 3A5*3FPb CTTTAAAGAGCTCTTTTGTCTCTCA
3A5*3RP GAAGCCAGACTTTGATCATTATGTTATG
CYP3A4*17 Exon 7 3A4*17FP CTGGACATGTGGGTTTCCTGT
3A4*17RP AGCAGTTATTTTTAAGAGAGAAAGATAAAT
FP, forward primer; RP, reverse primer.
a Oligonucleotides were designed based on the sequence in GenBank under accession number NG_000004.1.
b The restriction enzyme BseMII site was introduced with a mismatch oligonucleotide (underlined).
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trol of pCR2.1 TOPO plasmid construct containing a PCR-
amplified CYP3A4*17 fragment (Fig. 4C, lane 2).
New CYP3A5*3 Genotyping Test. Initial trials of a
PCR-RFLP for CYP3A5*3 based on literature methods
(Fukuen et al., 2002; Balram et al., 2003) resulted in complex
profiles due to incomplete digestion with DdeI (data not
shown). Intron 3 sequences from CYP3A5, CYP3A4, CYP3A7,
and CYP3A43 containing the corresponding CYP3A5*3 se-
Fig. 1. CO difference spectrum
of CYP3A4*1 wild type (A) and
CYP3A4*17 allelic protein (B).
DH5 E. coli competent cells
were transformed with recom-
binant pCW vector containing
each CYP3A4 allele. After 72 h
expression, the P450 was puri-
fied as described earlier (Lee et
al., 2003). The eluted P450 was
measured by a DW-2000 spec-
trophotometer. CYP3A4*1 pro-
tein shows a single absorption
at 450 nm. The CYP3A4*17
protein exhibited a major peak
at 450 nm and a small peak at
420 nm.
Fig. 2. Nifedipine metabolism by CYP3A allelic proteins.
CYP3A4*1 and variant alleles were expressed in E. coli and
purified as described under Materials and Methods. Puri-
fied P450 (10 pmol), human reductase (40 pmol), and cyto-
chrome b5 (20 pmol) were reconstituted as described under
Materials and Methods. To avoid intra-assay variations,
P450s were expressed, purified, and assayed together as
sets. Results are representative of two separate experi-
ments with separately purified preparations of allelic pro-
teins (the second set also exhibited the same pattern as
shown). Nifedipine metabolism was measured at two con-
centrations, one near the S50 (30 M) and the other near
the Vmax (200 M). All values are the mean 
 S.E. of
triplicate assays. , significantly lower (P 	 0.05) than
CYP3A4*1 wild type using Dunnett’s test.
Fig. 3. Kinetic assessment of nifedipine oxidation by
CYP3A4*1 and CYP3A4 allelic proteins. All reactions were
performed with 10 pmol of P450, 40 pmol of human reduc-
tase, and 20 pmol of cytochrome b5 in 0.1 ml of reaction for
10 min. Details of reaction procedures are described under
Materials and Methods. P450 alleles are indicated as
CYP3A4*3 (F), CYP3A4*18 (Œ), CYP3A4*17 (E),
CYP3A4*19 (‚), and CYP3A4*1 (). Values plotted are the
means 
 S.E. of triplicate experiments, except for the
P467S which was the mean of duplicate determinations.
Details for kinetic equations are described under Materials
and Methods. Data for CYP3A4 F189S is enlarged in the
down inset.
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quence were obtained from GenBank (accession number
NG_000004.1) and aligned using Vector NTI 8.0. As shown in
Fig. 5, there is a strong likelihood of nonspecific amplification
of other CYP3A forms when using the published primers,
since the reverse primer (shown with dashed box) does not
differentiate between CYP3A4, CYP3A5, or CYP3A7 and the
forward primer contains only one mismatch four bases from
the 5 end. In the present study, a new more specific PCR-
RFLP for CYP3A5*3 was designed to differentiate the AG
change in genomic DNA samples. A mismatched nucleotide
in a forward primer four bases from the 3 end was used to
introduce a BseMII recognition site specific for CYP3A5*3.
DNA sequencing of the PCR product for CYP3A5*3 from the
new pair of primers confirmed the specific amplification of
CYP3A5. These primers produced a single band at 197 bp
without nonspecific bands (Fig. 6C, lane 5). A DNA sample
known to be heterozygous for CYP3A5*3 produced two frag-
ments of 197 and 162 bp (Fig. 6C, lane 3). The DNA sample
containing CYP3A5*1/*1 remained undigested by BseMII as
shown in Fig. 6C, lane 4.
The Frequency of CYP3A4*17 and CYP3A5*3 in Cau-
casians. Only one individual of 72 from our original sequenc-
ing analysis (Dai et al., 2001) was found to carry the
CYP3A4*17 allele (1:24 Caucasians), and this individual was
also homozygous for CYP3A5*3 (Lee et al., 2003). This indi-
vidual was of Eastern European descent. In the present
study, further genotyping using a set of 100 Caucasian DNA
samples and 176 North American DNA samples revealed no
additional individuals carrying the CYP3A4*17 allele (0:552
alleles) (Table 3). In contrast, the frequency of the CYP3A5*3
TABLE 2
Kinetic properties of nifedipine oxidation by CYP3A4*1 and CYP3A4 coding variants
Reactions included 10 pmol of CYP3A4, 40 pmol of human reductase, 20 pmol of cytochrome b5, which were preincubated with 2 g of lipid mix at room temperature for 10
min, and then varying concentrations of substrate and 50 mM phosphate buffer (pH 7.7) were added. The reaction was initiated with 1 mM NADPH and incubated for 10
min at 37oC. Reactions were protected from light. Values represent the mean 
 S.E. of triplicate measurements, except for CYP3A4*19 which was the mean of duplicates.
Details of substrate concentrations and kinetic equations are described under Materials and Methods.
Oxidized Nifedipine
P450s Vmax S50 Hill Coefficient CLmax
nmol/min/nmol P450 M ml/min/nmol P450
CYP3A4*1 166 
 6 26.8 
 2.5 1.7 3.1
CYP3A4*3 202 
 8 32.6 
 3.1 1.6 3.2
CYP3A4*17 1.5 
 0.2 59.3 
 12 2.1 0.01
CYP3A4*18 155 
 5 25.3 
 2.1 1.7 3.1
CYP3A4*19 142 41.3 1.3 2.0
Fig. 4. Diagram for the detection of CYP3A4*17 in human genomic DNA by PCR amplification of exon 7 followed by BpmI digestion. Detailed
procedures are described under Materials and Methods. A, strategy for genotyping CYP3A4*17 by PCR-RFLP. B, the predicted sizes of the digested
DNA fragments for the various genotypes. C, the actual sizes of the BpmI-digested PCR products. Lane 1, 100-bp ladder; lane2, CYP3A4*17/*17
plasmid positive control exhibiting two bands after BpmI digestion; lane 3, heterozygous CYP3A4*17/*1 individual exhibiting all three bands after
BpmI digestion; lane 4, homozygous CYP3A4*1/*1 individual exhibiting a single band after BpmI digestion; lane 5, PCR product of heterozygous
CYP3A4*17/*1 individual without BpmI digestion, showing a specific single band.
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allele was 94.2 
 1.6 and 91.2 
 1.8% (
 standard error),
respectively, in these two populations. Since the original
finding of CYP3A4*17 was from an Adygei individual from
the Coriell set, a total of nine DNA samples from the Adygei
ethnic group available from Coriell was purchased and ana-
lyzed. Our PCR-RFLP test showed two of nine Adygei indi-
viduals carrying the CYP3A4*17 allele (11% frequency), in-
cluding the one first identified. Of two individuals carrying the
CYP3A4*17 allele, one was homozygous for the CYP3A5*3 al-
lele and the other was heterozygous for CYP3A5*3. Five of the
nine individuals were homozygous for CYP3A5*3 and the other
four were heterozygous for this allele (14:18 alleles) (78% fre-
quency), further suggesting that the CYP3A4*17 and more fre-
quent CYP3A5*3 splice variant may be present on the same
chromosome representing a defective CYP3A haplotype.
Discussion
It is well known that the metabolism of CYP3A substrates
varies by 40 to 60% in vivo (Wrighton et al., 1990; Shimada et
al., 1994; Hustert et al., 2001; Kuehl et al., 2001; Koch et al.,
2002), but there is limited evidence linking individual under-
lying genetic mutations to variations in metabolism.
CYP3A5*3, a splice variant responsible for decreased hepatic
expression of CYP3A5 protein in some individuals, occurs
with high frequency in many populations including Cauca-
sians (Kuehl et al., 2001). A higher oral tacrolimus clearance
has been found in patients with a CYP3A5*1 allele compared
with homozygous CYP3A5*3 (Hesselink et al., 2003; Thervet
et al., 2003; Zheng et al., 2003). Several studies have identi-
fied protein-coding variants of CYP3A4. Recombinant
CYP3A4*2 (S222P) exhibits a lower Vmax for nifedipine me-
tabolism (36% decrease) but not for that of testosterone
when compared with CYP3A4 wild type (Sata et al., 2000).
CYP3A4*4 (I118V), CYP3A4*5 (P218R), and CYP3A4*6 (a
premature stop codon) were found in a Chinese population;
the metabolite ratio of 6-hydroxycortisol to free cortisol in
the urine of mutant subjects was higher than those of wild-
type subjects (Hsieh et al., 2001). However, the overlapping
substrate specificity of CYP3A4 and CYP3A5 generally ap-
pears to partially mask phenotypic expression of a defect in
only one gene.
The present study shows that recombinant CYP3A4*17 is
markedly defective in nifedipine metabolism in vitro, exhib-
iting a 99% decrease in the Vmax and CLmax. In a previous
study, CYP3A4*17 (with 2% allelic frequency in Caucasians)
exhibited lower activity for both testosterone (70% decrease)
and the insecticide chlorpyrifos than wild type (Dai et al.,
2001). However, this study used a single 14C-testosterone
concentration of 25 M, which is below the Km and may have
underestimated the magnitude of the defect. The complete
kinetic analysis in the present study demonstrates more
conclusively that the CYP3A4*17 allele is markedly defec-
tive. Moreover, the possible association of this allele on a
single haplotype with the defective CYP3A5*3 splice variant
in two individuals from Eastern Europe (Adygei) is reported
in this study. This haplotype could result in defective metab-
olism of many CYP3A substrates including drugs and envi-
ronmental chemicals such as organophosphate insecticides in
vivo, since CYP3A5 and CPY3A4 would not compensate for
each other. CYP3A4 and CYP3A5 are important in the me-
tabolism of many insecticides including organophosphate in-
secticides such as chlorpyrifos, parathion, diazinon, and
phorate (reviewed in Hodgson, 2003).
The mechanism of the effect of the F189S coding change on
metabolism of the CYP3A4 substrates is not known. Exami-
nation of the crystal structure of human CYP3A4 (Yano et
al., 2004) indicates that this amino acid is not located in the
active site cavity of CYP3A4. It is located at a turn at the
C-terminal end of the E helix and appears to be involved in
packing with residues on helices G and H and the turn
between helices G and H. The alignment of this amino acid
with other CYP3As in different species indicates that the
phenylalanine is conserved across species (data not shown).
Its involvement with packing could result in influences on
other parts of the protein, causing conformational changes
that affect structure and indirectly affect activity.
The CYP3A4*3 (4% allelic frequency in Caucasians) and
the CYP3A4*19 allelic proteins (2% frequency in Asians)
exhibit normal metabolism of nifedipine, whereas recombi-
nant CYP3A4*18 (2% allelic frequency in Asians) exhibited a
2-fold higher activity toward testosterone and chlorpyrifos in
an earlier study (Dai et al., 2001). However, this variant
showed no significant change in metabolism of nifedipine
compared with wild type in the present study. Although this
difference could reflect the existence of multiple substrate
recognition sites on CYP3A4, the preliminary increase in
activity reported in the earlier study was based on only one
P450 purification and one substrate concentration. There-
fore, earlier results may have reflected batch to batch varia-
tion in P450 preparations.
Although there are variations in estimates of the relative
importance of CYP3A4 and CYP3A5 in the literature (Shi-
mada et al., 1994; Evans and Relling, 1999; Kuehl et al.,
2001), these P450s have overlapping substrate specificity
(Wrighton et al., 1990; Li et al., 1995; Evans and Relling,
Fig. 5. Design of CYP3A5*3 genotyping test. Genomic DNA sequences for
CYP3A4, CYP3A5, CYP3A7, and CYP3A43 were obtained from GenBank
(accession number NG_000004.1). The DNA sequence for CYP3A43 was
from the reverse complementary sequence. The sequence shaded in gray
represents nonidentical nucleotides. DNA fragments flanking CYP3A5*3
regions were aligned as described under Materials and Methods. New
specific genotyping primers for the detection of CYP3A5*3 are indicated
with the black shaded background and solid line arrows. Dashed line
arrows and boxes indicate CYP3A5*3 genotyping primers from a test
reported in the literature (Fukuen et al., 2002; Balram et al., 2003). The
AG mutation indicated by an asterisk and a mismatched nucleotide
(underlined) in the forward primer create a BseMII site. The location of
the BseMII cut site is indicated by a vertical arrow.
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1999; Gibson et al., 2002; Koch et al., 2002). Since most
CYP3A substrates are metabolized by both CYP3A4 and
CYP3A5 in humans, individuals expressing defective alleles
for both CYP3A4 and CYP3A5 would have a decreased drug
metabolism for many important clinical drugs and environ-
mental substrates. Therefore, PCR-RFLP genotyping tests
were designed for the detection of CYP3A4*17 and
CYP3A5*3. In our hands, a currently utilized PCR-RFLP for
CYP3A5*3 (Fukuen et al., 2002; Balram et al., 2003) did not
distinguish the hetero- and homozygous mutation of
CYP3A5*3 due to complete homology of the reverse primer
with CYP3A4, CYP3A5, and CYP3A7. We developed a new
specific PCR-RFLP genotyping test for the CYP3A5*3 muta-
tion. A second published PCR-RFLP genotyping method for
CYP3A5*3 (King et al., 2003) also uses specific primers for
CYP3A5 but requires the use of a 10% polyacrylamide gel
and a longer duration of electrophoresis (16 h) to detect an
8-bp difference in PCR products. The present genetic tests
will be useful for future clinical studies to investigate the
effects of mutations in CYP3A4*17 and CYP3A5*3 on the
metabolism of CYP3A substrates in vivo.
Genotyping of 276 Caucasian DNAs from the United
States (North Carolina) and the Coriell repository for
CYP3A4*17 revealed no individuals carrying this allele.
However, two individuals with the CYP3A4*17 allele were
found in nine Caucasians belonging to the Adygei ethnic
minority. According to ALFRED Detailed Record information
(http://alfred.med.yale.edu/alfred/recordinfo.asp), the Ady-
gei, an ethnic group of the Russian Caucasus, can be traced
back to at least the 6th century. Since they were conquered
by the Russian Empire in the 19th century, much of the
Adygei population was forced to immigrate to Turkey and
other Middle Eastern countries (Chang et al., 1996; Popova
et al., 2001). Of the original 1.2 million individuals, approx-
imately 800,000 survived the exodus. A few also live in the
United States in New Jersey (10,000). All of the nine Rus-
sian Adygei DNAs contained the CYP3A5*3 splice variant
(14:18 alleles) which is known to have a high frequency in
Caucasian populations. The CYP3A4*17 occurred at a fre-
quency of 2:18 alleles suggesting a second haplotype contain-
ing both CYP3A4*17 and CYP3A5*3 on the same chromo-
some (one individual was homozygous for CYP3A5*3 and the
Fig. 6. Diagram for the detection of CYP3A5*3 in human genomic DNA by PCR amplification of intron 3 followed by BseMII digestion. Detailed
procedures are described under Materials and Methods. A, strategy for genotyping CYP3A5*3 by PCR-RFLP. B, the predicted sizes of the digested
DNA fragments for various genotypes. C, the actual sizes of BseMII-digested PCR products. Lane 1, 100-bp ladder; lane 2, homozygous CYP3A5*3/*3
individual showing one band of 162 bp after BseMII digestion indicating complete digestion (the 35-bp fragment is too small to be seen); lane 3,
heterozygous CYP3A4*3/*1 individual showing two bands of 162 and 197 bp after BseMII digestion; lane 4, wild-type DNA after BseMII digestion;
lane 5, PCR product of homozygous CYP3A5*3/*3 individual without BseMII digestion, showing an undigested band of 197 bp.
TABLE 3
Genotype frequencies of CP3A4*17 and CYP3A5*3 alleles in various Caucasian groups
Group
Genotype (Number of Individuals Carrying the Genotype/Total Number of Subjects Examined)
CYP3A5*1/*1 CYP3A5*1/*3 CYP3A5*3/*3 CYP3A4*1/*1 CYP3A4*1/*17 CYP3A4*17/*17
North Carolina 0/124 22/124 102/124 176/176 0/176 0/176
Coriell 1/96 9/96 86/96 100/100 0/100 0/100
Adygei 0/9 4/9 5/9 7/9 2/9 0/9
308 Lee et al.
other individual was heterozygous for CYP3A5*3). Therefore,
we predict that a portion of Adygei populations (particularly
those homozygous for poor metabolizer alleles of both CYP3A
genes) could be at high risk to clinical drugs and to environ-
mental chemicals such as organophosphate insecticides.
The present study describes a putative defective
CYP3A4*17 allele was found with a moderate frequency
(11%) with the defective CYP3A5*3 splice variant (frequency
of 78%) in the Adygei, an ancient Caucasian ethnic group
which originated in Russia, but migrated to Turkey, and
several other Middle Eastern countries as well as certain
regions of the United States and Germany. We predict that
the coexistence of this allele in moderately frequent putative
defective haplotype (2:18 individuals) with the CYP3A5*3
allele in these populations may result in lower CYP3A activ-
ity in vivo. The clinical effects and environmental risk of
these two defective alleles should be addressed in future
studies in man in the Adygei and related ethnic groups.
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